BriaCell Therapeutics Corp.
$3.06
The Read: BriaCell's stock fell about 13% after Q1 2026 results due to cash burn concerns despite FDA clearance and trial progress, but surged over 240% following positive Phase 2 data showing a 55% greater than 1-year survival in metastatic breast cancer.
Price
Overlays
Panel
BCTX
Hover to view data
No Data